G9pharma co., LTD reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was KRW 2,424 million compared to KRW 5,121.42 million a year ago. Basic loss per share from continuing operations was KRW 594 compared to KRW 1,256 a year ago.

Diluted loss per share from continuing operations was KRW 594 compared to KRW 1,256 a year ago. Basic loss per share was KRW 594 compared to KRW 1,256 a year ago.